Satsuma Pharmaceuticals, Inc.

Jun 19, 2025

Satsuma Pharmaceuticals and SNBL Announce Four Abstracts to be Presented at the American Headache Society's 67th Annual Scientific Meeting

Apr 30, 2025

Satsuma Pharmaceuticals Announces U.S. FDA Approval for Atzumi(TM) (Dihydroergotamine) Nasal Powder for the Acute Treatment of Migraine

Nov 26, 2024

Satsuma Pharmaceuticals and SNBL Receive FDA Acceptance of NDA Resubmission of STS101 for the Acute Treatment of Migraine With or Without Aura

Sep 17, 2019

Satsuma Pharmaceuticals, Inc. Announces Closing of Initial Public Offering

Sep 12, 2019

Satsuma Pharmaceuticals, Inc. Announces Pricing of Initial Public Offering of Common Stock

Sep 03, 2019

Satsuma Pharmaceuticals Announces Poster Presentations at the International Headache Congress

Sep 03, 2019

Satsuma Pharmaceuticals, Inc. Announces Proposed Initial Public Offering of Common Stock

Aug 22, 2019

Satsuma Pharmaceuticals Announces First Patient Dosed in EMERGE(TM), a Phase 3 Efficacy Trial of STS101 for the Acute Treatment of Migraine

Jul 08, 2019

Satsuma Pharmaceuticals Announces Presentation of STS101 (Dihydroergotamine Nasal Powder) Phase 1 Trial Results at American Headache Society's Annual Scientific Meeting

Apr 24, 2019

Satsuma Pharmaceuticals Raises $62 Million in Series B Preferred Stock Financing